Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

Research & Selected Publications

Understanding the Tumor Microenvironment and Therapy Resistance in Head and Neck Squamous Cell Carcinoma
Authors:

Bagchi A, Ray RB

Journal & Year:

Cells | 2025

Long non-coding RNAs as therapeutic targets in head and neck squamous cell carcinoma and clinical application
Authors:

Tran ET, Patel RA, Chariyamane A, Ray RB

Journal & Year:

FEBS Open Bio | 2025

Targeting Triple-Negative Breast Cancer with Momordicine-I for Therapeutic Gain in Preclinical Models
Authors:

Kesh K, Tran ET, Patel RA, Ma CX, Ray RB

Journal & Year:

Cancers (Basel) | 2025

Silmitasertib in Combination With Cabozantinib Impairs Liver Cancer Cell Cycle Progression, Induces Apoptosis, and Delays Tumor Growth in a Preclinical Model
Authors:

Haga Y, Ray R, Ray RB

Journal & Year:

Mol Carcinog | 2025

Momordicine-I suppresses head and neck cancer growth by modulating key metabolic pathways
Authors:

Bandyopadhyay D, Tran ET, Patel RA, one or more additional authors omitted Ray RB

Journal & Year:

Cell Commun Signal | 2024

Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Authors:

Sur S, Bhartiya P, Steele R, one or more additional authors omitted Ray RB

Journal & Year:

Mol Cancer Ther | 2024

Increased expression of long non-coding RNA FIRRE promotes hepatocellular carcinoma by HuR-CyclinD1 axis signaling
Authors:

Haga Y, Bandyopadhyay D, Khatun M, one or more additional authors omitted Ray RB

Journal & Year:

J Biol Chem | 2024

NOTCH localizes to mitochondria through the TBC1D15-FIS1 interaction and is stabilized via blockade of E3 ligase and CDK8 recruitment to reprogram tumor-initiating cells
Authors:

Choi HY, Zhu Y, Zhao X, one or more additional authors omitted Ray R, one or more additional authors omitted Machida K

Journal & Year:

Exp Mol Med | 2024